Fundz

Lysogene Secures A €4.3 Million Non-Dilutive Financing From Bpifrance To Support Its Development

PRIVATENov 26, 2021

Amount Raised

€4.3 Million

Round Type

Seed

BiotechnologyHealth CareScience And Engineering

Description

Regulatory News:

Quick answer

Lysogene raised €4.3 Million in a Seed round, dated November 26, 2021.

How much did Lysogene raise?
Lysogene raised €4.3 Million in a Seed round on November 26, 2021.
What does Lysogene do?
Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS).
Who are the decision-makers at Lysogene?
Fundz holds 2 contacts at Lysogene, including the Cofounder. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Science And Engineering and Biotechnology around the same time

Companies in the same sectors as Lysogene that raised within 45 days of this round, from Fundz verified event records.

  • Maze Therapeutics raised $190M (Funding Round) on January 10, 2022.
  • AN2 Therapeutics raised $80M (Series B) on January 7, 2022.
  • Wheeler Bio raised $14M (Seed) on January 4, 2022.
  • Bond Biosciences raised $6.8M on January 3, 2022.
  • Trait Biosciences Inc. raised an undisclosed amount (Series A) on December 30, 2021.
  • TandemAI raised $25M (Seed) on December 22, 2021.

Who to call at Lysogene, and when

A new round usually means Lysogene is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Lysogene raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Lysogene, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Lysogene. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Lysogene

About

Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable a delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing. An adaptive clinical trial in GM1 gangliosidosis is ongoing. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene has also entered into an exclusive worldwide license agreement with SATT Conectus for a gene therapy candidate for the treatment of the Fragile X syndrome, a genetic disease related to autism. www.lysogene.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Lysogene raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsSamantha P., CofounderSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Lysogene's next move

See what Strategic adds

Lysogene raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.